All tickers · Prices as of Oct 23, 1:30 PM CT · filings and analysis as of Oct 22, 5:19 PM CT · live price, free
LLY · Eli Lilly and Company
Smart-money verdict: MIXED 1 of 4 cohorts bullish, 2 bearish
Mixed on LLY — 1 of 4 cohorts bullish, 2 bearish (bullish: institutions; bearish: insiders, Congress)
Congress trades (90 days)
BEARISH
5 disclosed congressional trades on LLY (last 90d): 1 buys, 4 sells
See it live, free →Insiders (SEC Form 4, 90 days)
BEARISH
LLY: 0 insider buy(s) $0 vs 3 sell(s) $15,958,170 in last 90d — bearish — insiders selling heavily
See it live, free →Wall St analysts
NEUTRAL
Buy consensus, 83.9% buy ratings, +1.9% target upside
See it live, free →Big funds (13F)
BULLISH
Institutions leaned to accumulation last quarter — 4 of the top 10 holders added, 1 trimmed.
See it live, free →Stock signal (EquityScope)
BUY
$1264.67, -3.4% today, +5% to analyst target. Analysis (2026-10-22): LLY trades near its 52-week high at $1,306.69, with a trailing P/E of 43.9 that compresses to 27.7 on forward earnings, so the market is pricing in strong continued growth rather than paying a premium
See it live, free →
Recent Congress trades in LLY
| Member | Chamber | Type | Amount | Traded |
|---|
| John Boozman | Senate | SELL | $1,001 - $15,000 | 2025-11-21 |
| Michael Rulli | House | SELL | $1,001 - $15,000 | 2026-07-01 |
| Michael Rulli | House | BUY | $1,001 - $15,000 | 2026-01-02 |
| Michael Rulli | House | SELL | $1,001 - $15,000 | 2025-12-02 |
| Tommy Tuberville | Senate | SELL | $15,001 - $50,000 | 2025-04-15 |
| Dan Newhouse | House | SELL | $1,001 - $15,000 | 2026-07-10 |
STOCK Act disclosures arrive 25-45 days after the trade. Insider data from SEC Form 4 (open-market buys and sells only, not grants). Analyst consensus is current.
Data, not investment advice. LoneStarOracle LLC.